Emcure Pharmaceuticals L

NSE: EMCURE · Pharmaceuticals · sector

₹1,780.20NSE close 2026-10-26

Key numbers

Market cap₹33,767 cr

Price₹1,780.20

52w high / low₹2,101 / ₹1,306

P/E33.4xSector median 27.9x

P/B6.8xSector median 2.9x

Book value₹261.0

Dividend yield0.17%Sector median 0.48%

ROE21.5%Sector median 11.7%

ROCE25.0%Sector median 12.3%

OPM20.2%Sector median 14.0%

Debt / equity0.24xSector median 0.16x

EV/EBITDA17.8xSector median 18.6x

Interest cover10.4x

Current ratio1.46x

Sales growth 3y–Sector median +9.6%

Profit growth 3y–Sector median +13.3%

PEG0.93x

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

Cash ₹148 cr vs borrowings ₹1,204 cr (FY26): borrowings are higher by ₹1,057 cr.
Operating profit covered interest 10.4x in the last 12 months.
0.04% of the promoters' shares are pledged (0.0% of all shares).
Revenue was higher than a year earlier in 4 of the last 4 quarters.
Other income was 1% of net profit in the last 12 months.
Dividend paid in 1 of the last 2 financial years.
Price ₹1,780.20 on 2026-10-26: -15.3% from the 52-week high, +36.3% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹2,009.60 · low ₹905.60

Quarterly results

₹ cr	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	2,002	1,963	2,116	2,101	2,270	2,363	2,470	2,580
EBITDA	381	355	392	413	475	455	490	532
OPM %	19.0%	18.1%	18.5%	19.7%	20.9%	19.2%	19.8%	20.6%
Other income	36	4	4	4	3	2	4	2
Net profit	195	154	189	207	243	231	243	294
EPS (₹)	10.33	8.12	9.97	10.92	12.85	12.16	12.84	15.50
Revenue YoY					+13.4%	+20.4%	+16.7%	+22.8%
Profit YoY					+25.1%	+50.0%	+28.8%	+42.1%

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	FY25	FY26	TTM
Revenue	7,896	9,204	9,683
EBITDA	1,464	1,833	1,952
Net profit	681	924	1,011
EPS (₹)	36.43	48.77	53.35
Revenue growth		+16.6%	+18.4%
Profit growth		+35.7%	+35.9%
Dividend / share (₹)	–	3.00

Compounded growth	3 years	5 years	Last 12 months
Sales	–	–	+18.4%
Net profit	–	–	+35.9%
EPS	–	–	–
Share price	–	+9.9% (2y)	+26.0%

Balance sheet

₹ cr	FY25	FY26
Shareholders' equity	4,446	4,950
Borrowings	732	1,204
Cash & equivalents	241	148
Total assets	8,233	9,612
Fixed assets	1,954	1,960
Capital work in progress	124	172
Investments	19	20
Receivables	2,002	2,563
Inventory	1,932	2,398
Payables	1,480	1,808

Year-end figures from the March annual filing.

Cash flow

₹ cr	FY25	FY26
Cash from operations	852	944
Cash from investing	-94	-1,193
Cash from financing	-814	343
Capex	407	548
Free cash flow	445	396

Free cash flow = cash from operations − capex.

Ratios by year

₹ cr	FY25	FY26
ROE %	15.3%	18.7%
ROCE %	22.2%	23.2%
Debtor days	93	102
Inventory days	224	239
Payable days	172	180
Cash conversion cycle (days)	145	161
Working capital days	92	71

Shareholding

Holder	% (2026-09-30)
Promoters	77.82%
FIIs	4.94%
DIIs	8.49%
of which Mutual funds	7.05%
of which Insurance	1.19%
Public (non-institutions)	8.75%

Quarter	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters %	77.94%	77.92%	77.91%	77.88%	77.87%	77.87%	77.83%	77.82%

Promoter group	%
Satish R Mehta	39.74%
Everest Trust (Shares held by Sanjay Rajanikant Mehta with Sonali Sanjay Mehta, as trustees)	7.65%
Unity Trust (Shares held by Sunil Rajanikant Mehta with Kamini Sunil Mehta, as trustees)	7.65%
Samit Satish Mehta	7.14%
Bhavana Satish Mehta	4.70%
Namita Vikas Thapar	2.67%
Pushpa Rajnikant Mehta	2.05%
Sanjay Rajanikant Mehta	1.95%
Sunil Rajanikant Mehta	1.50%
Kamini Sunil Mehta	0.88%
Rutav Sunil Mehta	0.55%
Niraj Sunil Mehta	0.55%
Vikas M Thapar	0.34%
Surekha Umakant Shah	0.17%
Shah Suhasini Saumil	0.07%

Public holders above 1%	%
Kotak Midcap Fund	2.31%
Aditya Birla Sun Life Mutual Fund - Aditya Birla Sun Life Elss Tax Saver Fund	1.45%
Nippon Life India Trustee Ltd-A/C Nippon India Multi Cap Fund	1.19%
Government Pension Fund Global	1.05%

1,29,328 shareholders. Pledged: 0.04% of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
EMCURE	₹33,767 cr	33.4x	6.8x	21.5%	25.0%	20.2%	–	0.17%

All 185 companies in Pharmaceuticals →

Dividends & corporate actions

Ex-date	Action	Detail
2026-09-04	Dividend	Dividend - Rs 3.60 Per Share
2025-08-14	Dividend	Dividend - Rs 3 Per Share

Documents

Links go to the original files on the exchange website.

About the company

Manufacturing: Manufacture of pharmaceuticals, medicinal chemical and botanical products


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	EMCURE
BSE code	544210
ISIN	INE168P01015
Face value	₹10.0
Incorporated	1981-04-16
Website	www.emcure.com
Plants (India / abroad)	9 / 0

From the company's filings (BRSR FY26).

Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.